📋 Tender Overview
Scalable Microbial Metabolite Discovery Through Synthetic Biology
The discoveries of microbial secondary metabolites (SM) led to an incalculable impact on human health and lifespan. A large share of the antibiotics, anticancers and immunosuppressants in use today originate from microorganisms. However, discoveries of SMs of microbial origin through traditional approaches have declined in the past decades, depriving drug pipelines from a key source of bioactive molecules. The consequences are dire, in particular in the case of antibiotics. Encouragingly, the study of the biosynthetic genes responsible for the synthesis of SMs indicates that the natural repertoire remains vastly underexplored, and new ways to access it are enabled by DNA technologies.
Funded Under
European Research Council (Erc)
Total Cost
€ 1 490 250,00
Eu Contribution
€ 1 490 250,00
Coordinated By
Institut National De La Sante Et De La Recherche Medicale
France
